Market Overview

Presbia Chief Technology Officer Vladmir Feingold to Present on Presbia Flexivue Microlens at Ophthalmology Innovation Summit





Presbia's Chief Technology Officer and Inventor of the Presbia Flexivue Microlens will present on the company's progress in the development of its safe, effective and reversible corneal inlay solution at the 4th Annual Ophthalmology Innovation Summit



Thursday, November 8, 2012

Private Device Company Showcase: 7:45-9:30 a.m. (Presentation: 8:25 a.m.)



Chicago Marriott Downtown Magnificent Mile



Sarah Troutt

Office: +1 (212) 397-1030

Mobile: +1 (917) 664-0319

On Thursday, November 8, 2012, Presbia's Chief Technology Officer will present on the Presbia Flexivue Microlens at the 4th Annual Ophthalmology Innovation Summit during the Annual Meeting of the American Academy of Ophthalmology in Chicago, Illinois. The Ophthalmology Innovation Summit brings together leading companies that specialize in the development of ophthalmic products, drugs and devices with a distinguished group of innovators/entrepreneurs, clinicians, venture capitalists, senior R&D and business development executives from private and public companies.

Mr. Feingold, inventor the Presbia Flexivue Microlens, will speak about latest developments and clinical results of Presbia's corneal inlay solution for presbyopia, or the age-related deterioration of near vision, as well as its current efforts to pursue commercialization in the U.S. and around the world.

Since 2009, when it received its CE Mark, the Presbia Flexivue Microlens has been commercially available in 40 countries across Europe and Latin America. More than 250 patients have had the lens implanted, the vast majority of whom have reported exceptionally high satisfaction with the surgically implantable lens alternative to reading glasses.


Presbia is a leading ophthalmic-device company focused on the development of solutions for presbyopia, the age-related loss of the ability to read or focus on near objects. Chief among these approaches is the Presbia Flexivue Microlens, a 3mm-diameter lens that is implanted in the corneal stroma of the patient's non-dominant eye using femtosecond laser technology. The less than 10-minute procedure requires no general anesthesia, and the patient's visual recovery takes only a couple of days. Since the Presbia Flexivue Microlens solution utilizes standard equipment and requires minimal additional training, the procedure requires no significant capital investment by the surgeon's practice.

Further information is available at

Note: Not Available for Sale in the United States.

Sarah Troutt
Office: +1 (212) 397-1030
Mobile: +1 (917) 664-0319

View Comments and Join the Discussion!